Christine S. Rollier
Associate Professor in Vaccinology
- Research Scientist – Team Head
- Preclinical and early clinical novel vaccine development
- Jenner Investigator
Christine Rollier is a senior research scientist in Vaccinology at the Oxford Vaccine Group, leading the Novel Vaccine Development team involved in the creation, design, preclinical and early clinical studies of new and improved vaccines against bacterial diseases and infectious diseases affecting children.
She studied biochemistry and obtained her PhD at the University of Lyon I in 2000, with a focus on DNA immunization as a therapeutic approach against chronic Hepatitis B Virus infection. She trained in immunology, specialising in vaccine development at Institut National de la Sante et Recherche Medicale (INSERM), Lyon, France. She proceeded to work on novel vaccine development and cellular immunity against Hepatitis C Virus chronic infection at the Biomedical Primate Research Center, The Netherlands for five years, before joining the Jenner Institute at the University of Oxford in 2007 as a senior immunologist, to work on improvements of vaccine vectors against malaria. She joined the Oxford Vaccine group in 2010, bringing her expertise of viral vectored vaccine platform and preclinical research, to work on meningococcal and preclinical vaccine development.
Her current research activities, funded by the Medical research Council, Innovate UK, the Oxford Biomedical Research Centre, and several charities, include the conception, design, pre-clinical and early clinical development of new and improved vaccines against bacterial infections such as caspular group B meningococcus, plague, Q fever, enteric fever, pertussis and Respiratory Syncitial Virus.
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nat Med, 27, 279 - 288
MAIT cell activation augments adenovirus vector vaccine immunogenicity.
Provine NM. et al, (2021), Science, 371, 521 - 526
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
Rollier CS. et al, (2020), Scientific Reports, 10
Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine.
O'Connor D. et al, (2020), Mol Syst Biol, 16